Morales-Angulo Carmelo, Pérez del Molino Alfonso, Zarrabeitia Roberto, Fernández Africa, Sanz-Rodríguez Francisco, Botella Luisa María
Unidad de THH, Hospital Sierrallana, Torrelavega, Cantabria, España.
Acta Otorrinolaringol Esp. 2007 Apr;58(4):129-32.
Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT). Its treatment occasionally presents difficulties as there is no consensus on the appropriate therapeutic protocol. Our objective was to explore the utility of oral tranexamic acid for the treatment of epistaxes in HHT patients.
A 3-year prospective study was carried on HHT patients with epistaxis treated with oral tranexamic acid in the HHT unit at our hospital.
Ten patients with HHT were treated with oral tranexamic acid during the study. Most of them improved both the frequency and severity of their epistaxis and were satisfied with the treatment. No treatment-related complications were recorded. Two patients needed more aggressive treatments to control epistaxis.
Oral tranexamic acid is useful for achieving significant reductions in epistaxis frequency and intensity in selected patients with HHT. In those presenting severe epistaxis, however, it may need to be combined with more aggressive therapies.
复发性鼻出血是遗传性出血性毛细血管扩张症(HHT)最常见的临床表现。由于在合适的治疗方案上尚未达成共识,其治疗偶尔会遇到困难。我们的目的是探讨口服氨甲环酸治疗HHT患者鼻出血的效用。
在我院的HHT科室对采用口服氨甲环酸治疗鼻出血的HHT患者进行了一项为期3年的前瞻性研究。
在研究期间,10例HHT患者接受了口服氨甲环酸治疗。他们中的大多数鼻出血的频率和严重程度均有所改善,并且对治疗感到满意。未记录到与治疗相关的并发症。2例患者需要更积极的治疗来控制鼻出血。
口服氨甲环酸有助于显著降低部分HHT患者鼻出血的频率和强度。然而,对于那些出现严重鼻出血的患者,可能需要与更积极的治疗方法联合使用。